Finasteride
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Finasteride and local guidelines before prescribing.
Mechanism
5-alpha reductase type 2 inhibitor reducing dihydrotestosterone.
Uses
Benign prostatic hyperplasia, male-pattern hair loss.
Dosing
- … in days Postural hypotension , dizziness, retrograde ejaculation, floppy iris syndrome (tell the eye surgeon before cataract surgery) 5-alpha reductase inhibitor (finasteride, dutasteride) Enlarged prostate (over about 30 g, or PSA over 1.4) at high risk of progression; takes 6 months ; reduces retention and surgery Reduced …
Surgey: Urology - 5-alpha reductase inhibitor (finasteride, dutasteride) | Enlarged prostate (over about 30 g, or PSA over 1.4) at high risk of progression; takes 6 months ; reduces retention and surgery | Reduced libido, erectile dysfunction, gynaecomastia; halves PSA (double the value when interpreting)
Surgey: Urology - … PSA after counselling; frequency–volume chart. Treatment: lifestyle, alpha-blocker (tamsulosin) for moderate–severe voiding symptoms, 5-alpha reductase inhibitor (finasteride) if prostate is estimated >30 g or PSA >1.4; antimuscarinic or mirabegron for storage symptoms.
General Practice: Child health, women's health and men's health in primary care
Side effects
Reduced libido, erectile dysfunction, ejaculatory problems, gynaecomastia; mood changes.
Interactions
Few clinically important interactions.
Contraindications and cautions
Women of childbearing potential (handling), hypersensitivity
Monitoring
PSA at baseline, breast symptoms
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe liver impairment
Overdose and reversal
Supportive
Special advice
PSA falls by about half after 6 months; do not handle crushed tablets in pregnancy; breast changes need review.
More from the textbook: uses, cautions and other points
- Testosterone is converted to DHT (5-alpha-reductase - blocked by finasteride) and to oestrogen (aromatase - gynaecomastia).
Endocrine: Anatomy Physiology and Pharmacology - Anti-androgens - cyproterone acetate (liver toxicity, meningioma risk with high doses - MHRA), spironolactone (hirsutism), finasteride (5-alpha-reductase inhibitor - BPH; MHRA warning on depression and suicidal thoughts and sexual side effects).
Endocrine: Anatomy Physiology and Pharmacology - Anti-androgens (bicalutamide), finasteride, GnRH analogues.
Endocrinology: Reproductive - Growth depends on DHT (testosterone converted by 5-alpha-reductase - blocked by finasteride).
Renal: Anatomy, Physiology and Pharmacology - 5-alpha-reductase inhibitors ( finasteride , dutasteride) - shrink the prostate over 6 months or more ; for large prostates; halve the PSA (double it when interpreting); reduced libido, erectile dysfunction; finasteride - depression and suicidal thoughts (MHRA); women who could be pregnant shouldn't handle crushed or broken …
Renal: Anatomy, Physiology and Pharmacology - Lowered by: 5-alpha reductase inhibitors (finasteride, dutasteride - halve it).
Oncology: Urology and Genital cancers
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Reproductive (1 mention)
- Renal: Anatomy, Physiology and Pharmacology (3 mentions)
- Oncology: Urology and Genital cancers (2 mentions)
- Oncology: Breast and Gynae Cancers (1 mention)
- Oncology: Skin Cancer (1 mention)
- Psychiatry: Mood disorders (1 mention)
- Surgey: Urology (3 mentions)
- Clinical pharmacology and prescribing: Prescribing in special groups (2 mentions)
- General Practice: Child health, women's health and men's health in primary care (1 mention)